MA-OPTIKOS
12.9.2022 20:32:37 CEST | Business Wire | Press release
Optikos Corporation introduced three new products to its OpTest® and Meridian® lens and camera metrology product lines, developed to address the specific requirements for testing and image capture conditions in the field of automotive imaging.
Optikos has a long history of pioneering the development and commercialization of test equipment for the evaluation of lenses and cameras, including the OpTest® and LensCheck™ product families, widely regarded as the gold standard for assessing the image quality of lens assemblies; and the Meridian product line, for measuring the performance of an assembled camera. The Company is recognized not only for its comprehensive range of standard products, but also its readiness to customize hardware and software to suit a customer’s particular requirements such as those demanded in automotive imaging applications.
With two of its newest products, Optikos has extended its expertise in measuring the effects of stray light in lenses to camera assemblies—with the Meridian camera testing line now including products that serve as sources for measuring Veiling Glare Index (VGI) and Glare Spread Function (GSF).
VGI measurements are useful as a measure of diffuse irradiance on the image plane, and require a uniformly illuminated background field populated with one or more dark objects. The new Meridian VGI source is a customizable hemispherical integrating sphere into which light traps of various sizes may be fitted; and enables the customer to specify the sizes and locations of the light traps according to the characteristics of the camera assemblies to be tested. The system is illuminated using white LEDs, the intensity of which may be remotely controlled.
Glare Spread Function testing evaluates the severity of ghost reflections or other prominent stray light artifacts that form concentrated irradiation patterns. The new Meridian Sol-55 projector addresses this need with a modular design, and features interchangeable object aperture drawers for controlling the angular extent of the projected target, and an aperture wheel that controls the numerical aperture of the illumination through the object aperture. “The unique design avoids overfilling the lens under test and creating a secondary source of stray light from adjacent scattering surfaces; while illumination is provided by a high intensity white LED which can be remotely controlled for high dynamic range measurements,” said David Imrie, Optikos Chief Technology Officer.
Meridian Sol-55 projectors are designed to be flexibly mounted at pre-determined field points with respect to the device-under-test in rigid assemblies that form a Meridian Sunfield system. They are distinguished from Meridian Starfield assemblies of Static Target Projectors (STPs) used in image quality (MTF) testing of cameras.
In addition to stray light, temperature extremes pose a significant challenge for image sensor performance in automotive cameras. Optikos has been testing lenses across a range of temperatures in its IQ Lab™ Optical Testing Service since 2017, and first productized this process for testing lenses up to 150mm with its Thermal Module TM-1150 system.
The new TC-1065 is a thermal chamber used for lens testing that extends the maximum size of lenses that may be tested over a range of temperatures on a LensCheck system, complementing the smaller TC-1050 and TC-1010 products also available in the product line. In order to optimize the thermal performance, the thermal chamber is generally sized to match the dimensions of the lenses with which it will be used.
Optikos will be exhibiting at AutoSens Brussels 2022 on October 12-14th. To learn more about Optikos solutions for automotive imaging, see contact details below.
About Optikos
The Optical Engineering Experts®—Optikos provides leading-edge applications of optical technology to organizations worldwide. For customers who require optical testing and image quality assessment of lens and camera systems, we offer an advanced line of standard and custom metrology products as well as in-house IQ Lab™ Optical Testing Services. We offer product development services that include a broad range of engineering, contract manufacturing, and assembly capabilities. Our broad skill set, including optics, mechanics, electronics, automation, and software systems, enables us to quickly understand our customers' unique technical requirements and provide a flexible and scalable resource. Applications range from medical devices and diagnostics to aerial imaging, defense, automotive cameras, and well beyond.
For more information, visit optikos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005764/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom